In-Licensing Due Diligence

Summary

SciVida assisted a global specialty biopharmaceutical company focused on rare disease in its due diligence of a product it was considering in-licensing, elucidating potential pricing elasticity for the product as well as market access dynamics.

Situation

Our client, an established company in the rare disease space, was considering diversifying its portfolio through in-licensing of a novel asset indicated for a rare disease that had no approved treatments. The client wanted to understand pricing and market access potential for the new asset and how dynamics were impacted by the emergence of a key competitor that was expected to be first to market.

SciVida’s Approach

SciVida gathered and reviewed the client’s materials, and, given the imminent need for insights on which to base a go/no-go decision, our team jumped right into a working session with the core client team to identify and prioritize the key business questions and plan to generate the requisite insights, including a combination of desk research, third-party data analysis, and focused primary research.

Our team conducted secondary research to fill information gaps necessary to support the focused primary research with payers. In a short time, SciVida was able to gather critical insights on payer perceptions of the disease, the asset, and the key competitor; anticipated coverage and handling, including coverage considerations; and product benchmarks for pricing, price expectations, and price sensitivity.

Our due diligence support also included a risk analysis of value assessment by Institute for Clinical and Economic Review (ICER).

We synthesized the insights from our primary and secondary research and ICER risk analysis into key takeaways and considerations to support the client’s go/no-go decision.